Project Grant R01CA288521
Award Date
1/15/25
Completion Date
12/31/28
Dollars Obligated
$667K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award of $597,766.00 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop novel methods for dual-tracer PET imaging to better characterize cancer using a long-axial field-of-view PET scanner called the PennPET Explorer. The key objectives are to: 1) Develop protocols to image fluoroglutamine (a research radiotracer) with FDG in breast cancer patients, enabling quantification of glutamine metabolism alongside glucose...
This $665,435.00 Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) Federal Grant Program aims to develop a system capable of simultaneous multi-tracer Positron Emission Tomography (PET) imaging. The project will focus on enabling simultaneous PET imaging of multiple molecular probes by using tracers that emit both positrons and higher energy gamma photons. This will provide a more comprehensive understanding of biological processes in diseases like...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $554,188 to The Trustees of the University of Pennsylvania to develop silver telluride nanoparticle contrast agents for use in dual-energy mammography screening for breast cancer. The award will fund several key activities to advance these novel contrast agents towards clinical translation, including: Adapting the nanoparticle synthesis process for scalable production...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $549,536 to the Trustees of Dartmouth College to develop an innovative 3D wearable near-infrared (NIR) spectral tomography system. The objective is to create a clinical platform capable of early prediction of residual cancer burden in breast cancer patients undergoing neoadjuvant chemotherapy. The proposed technological innovations focus...
This $435,827 Project Grant from the National Cancer Institute (NCI) under the CFDA 93.394 Cancer Detection and Diagnosis Research program supports research conducted by New York University (NYU) School of Medicine to develop deep learning methods for analyzing mass spectrometry imaging (MSI) data. The goal is to make MSI data more accessible to existing machine learning workflows by expanding the dimensionality of the data structure to treat each metabolite or lipid as an individual "color...
The National Cancer Institute (NCI) awarded a $1,003,173 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Radiopharmaceutical Imaging and Dosimetry, LLC, a for-profit company based in Baltimore, Maryland. The grant funding will support the development of a prototype web/cloud-based quantitative SPECT reconstruction software system to enable precise imaging and dosimetry for emerging radiopharmaceutical cancer therapies, particularly those utilizing alpha-emitting...
This $432,889 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to advance molecular imaging and metabolic therapies for reversing cachexia induced by pancreatic ductal adenocarcinoma (PDAC). The research team at The Johns Hopkins University will focus on disrupting glutamine metabolism in PDAC models, studying the effects on tumor and organ metabolism, as well as changes in the tumor and spleen immune...
This $676,006 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund research to develop non-invasive imaging strategies to identify mechanisms of resistance to cancer immunotherapy early after treatment. The researchers will utilize PET imaging to measure markers of immune response and neutrophil levels, as well as implantable fluorescence sensors to continuously monitor these parameters in vivo. They will pair these molecular...
This National Cancer Institute (NCI) Project Grant award under CFDA 93.395 "Cancer Treatment Research" provides funding of $227,906 from January 1, 2025 to December 31, 2026 to The Trustees of the University of Pennsylvania to investigate the immunomodulatory effects of the FDA-approved drug Photofrin and other heme oxygenase-1 (HO-1) inducing agents in malignant pleural mesothelioma (MPM). The research aims to characterize the tumor control and antitumor immunity generated by...
This National Cancer Institute (NCI) Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" program will fund the development of a virtual multiplex immunofluorescence (MPIF) restaining algorithm, DeepLIIF, to improve the reproducibility and accuracy of PD-L1 immunohistochemistry (IHC) biomarker quantification. The $683,089 award to the Sloan-Kettering Institute for Cancer Research aims to incorporate MPIF immune cell markers, whole-cell segmentation, and large...